Selected research
Industry Research
Felbamate Industry Research Report 2026
Market perspective
The global Felbamate market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Felbamate is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Felbamate is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Felbamate is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Felbamate include Sun Pharma, Mylan, Schering Plough, Merck Sharp and Dohme, Corepharma, Cadila Healthcare, ANI Pharmaceuticals, Amneal Pharmaceuticals and Alvogen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Felbamate market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Felbamate Market by Company
Sun Pharma
Mylan
Schering Plough
Merck Sharp and Dohme
Corepharma
Cadila Healthcare
ANI Pharmaceuticals
Amneal Pharmaceuticals
Alvogen
Felbamate Segment by Type
Tablet
Oral Solution
Felbamate Segment by Application
Refractory Lennox-Gastaut Syndrome
Refractory Seizure Disorders
Others
Felbamate Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Felbamate market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Felbamate and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Felbamate.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Felbamate manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Felbamate by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Felbamate in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Tablet
- Oral Solution
Applications
- Refractory Lennox-Gastaut Syndrome
- Refractory Seizure Disorders
- Others
Companies covered
- Sun Pharma
- Mylan
- Schering Plough
- Merck Sharp and Dohme
- Corepharma
- Cadila Healthcare
- ANI Pharmaceuticals
- Amneal Pharmaceuticals
- Alvogen
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Felbamate Market Size (2021-2032)
- 2.2.2 Global Felbamate Sales (2021-2032)
- 2.2.3 Global Felbamate Market Average Price (2021-2032)
- 2.3 Felbamate by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Tablet
- 2.3.3 Oral Solution
- 2.4 Felbamate by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Refractory Lennox-Gastaut Syndrome
- 2.4.3 Refractory Seizure Disorders
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Felbamate Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Felbamate Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Felbamate Revenue of Manufacturers (2021-2026)
- 3.4 Global Felbamate Average Price by Manufacturers (2021-2026)
- 3.5 Global Felbamate Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Felbamate, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Felbamate, Product Type & Application
- 3.8 Global Manufacturers of Felbamate, Established Date
- 3.9 Global Felbamate Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sun Pharma
- 4.1.1 Sun Pharma Company Information
- 4.1.2 Sun Pharma Business Overview
- 4.1.3 Sun Pharma Felbamate Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sun Pharma Felbamate Product Portfolio
- 4.1.5 Sun Pharma Recent Developments
- 4.2 Mylan
- 4.2.1 Mylan Company Information
- 4.2.2 Mylan Business Overview
- 4.2.3 Mylan Felbamate Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Mylan Felbamate Product Portfolio
- 4.2.5 Mylan Recent Developments
- 4.3 Schering Plough
- 4.3.1 Schering Plough Company Information
- 4.3.2 Schering Plough Business Overview
- 4.3.3 Schering Plough Felbamate Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Schering Plough Felbamate Product Portfolio
- 4.3.5 Schering Plough Recent Developments
- 4.4 Merck Sharp and Dohme
- 4.4.1 Merck Sharp and Dohme Company Information
- 4.4.2 Merck Sharp and Dohme Business Overview
- 4.4.3 Merck Sharp and Dohme Felbamate Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Merck Sharp and Dohme Felbamate Product Portfolio
- 4.4.5 Merck Sharp and Dohme Recent Developments
- 4.5 Corepharma
- 4.5.1 Corepharma Company Information
- 4.5.2 Corepharma Business Overview
- 4.5.3 Corepharma Felbamate Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Corepharma Felbamate Product Portfolio
- 4.5.5 Corepharma Recent Developments
- 4.6 Cadila Healthcare
- 4.6.1 Cadila Healthcare Company Information
- 4.6.2 Cadila Healthcare Business Overview
- 4.6.3 Cadila Healthcare Felbamate Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Cadila Healthcare Felbamate Product Portfolio
- 4.6.5 Cadila Healthcare Recent Developments
- 4.7 ANI Pharmaceuticals
- 4.7.1 ANI Pharmaceuticals Company Information
- 4.7.2 ANI Pharmaceuticals Business Overview
- 4.7.3 ANI Pharmaceuticals Felbamate Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 ANI Pharmaceuticals Felbamate Product Portfolio
- 4.7.5 ANI Pharmaceuticals Recent Developments
- 4.8 Amneal Pharmaceuticals
- 4.8.1 Amneal Pharmaceuticals Company Information
- 4.8.2 Amneal Pharmaceuticals Business Overview
- 4.8.3 Amneal Pharmaceuticals Felbamate Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Amneal Pharmaceuticals Felbamate Product Portfolio
- 4.8.5 Amneal Pharmaceuticals Recent Developments
- 4.9 Alvogen
- 4.9.1 Alvogen Company Information
- 4.9.2 Alvogen Business Overview
- 4.9.3 Alvogen Felbamate Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Alvogen Felbamate Product Portfolio
- 4.9.5 Alvogen Recent Developments
5 Global Felbamate Market Scenario by Region
- 5.1 Global Felbamate Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Felbamate Sales by Region: 2021-2032
- 5.2.1 Global Felbamate Sales by Region: 2021-2026
- 5.2.2 Global Felbamate Sales by Region: 2027-2032
- 5.3 Global Felbamate Revenue by Region: 2021-2032
- 5.3.1 Global Felbamate Revenue by Region: 2021-2026
- 5.3.2 Global Felbamate Revenue by Region: 2027-2032
- 5.4 North America Felbamate Market Facts & Figures by Country
- 5.4.1 North America Felbamate Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Felbamate Sales by Country (2021-2032)
- 5.4.3 North America Felbamate Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Felbamate Market Facts & Figures by Country
- 5.5.1 Europe Felbamate Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Felbamate Sales by Country (2021-2032)
- 5.5.3 Europe Felbamate Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Felbamate Market Facts & Figures by Country
- 5.6.1 Asia Pacific Felbamate Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Felbamate Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Felbamate Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Felbamate Market Facts & Figures by Country
- 5.7.1 South America Felbamate Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Felbamate Sales by Country (2021-2032)
- 5.7.3 South America Felbamate Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Felbamate Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Felbamate Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Felbamate Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Felbamate Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Felbamate Sales by Type (2021-2032)
- 6.1.1 Global Felbamate Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Felbamate Sales Market Share by Type (2021-2032)
- 6.2 Global Felbamate Revenue by Type (2021-2032)
- 6.2.1 Global Felbamate Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Felbamate Revenue Market Share by Type (2021-2032)
- 6.3 Global Felbamate Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Felbamate Sales by Application (2021-2032)
- 7.1.1 Global Felbamate Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Felbamate Sales Market Share by Application (2021-2032)
- 7.2 Global Felbamate Revenue by Application (2021-2032)
- 7.2.1 Global Felbamate Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Felbamate Revenue Market Share by Application (2021-2032)
- 7.3 Global Felbamate Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Felbamate Value Chain Analysis
- 8.1.1 Felbamate Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Felbamate Production Mode & Process
- 8.2 Felbamate Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Felbamate Distributors
- 8.2.3 Felbamate Customers
9 Global Felbamate Analyzing Market Dynamics
- 9.1 Felbamate Industry Trends
- 9.2 Felbamate Industry Drivers
- 9.3 Felbamate Industry Opportunities and Challenges
- 9.4 Felbamate Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst